Small Cell Lung Carcinoma Clinical Trials

12 recruiting

Small Cell Lung Carcinoma Trials at a Glance

23 actively recruiting trials for small cell lung carcinoma are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Baltimore, Barcelona, and Valencia. Lead sponsors running small cell lung carcinoma studies include Boehringer Ingelheim, AstraZeneca, and Advenchen Laboratories Nanjing Ltd..

Browse small cell lung carcinoma trials by phase

Treatments under study

About Small Cell Lung Carcinoma Clinical Trials

Looking for clinical trials for Small Cell Lung Carcinoma? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Small Cell Lung Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Small Cell Lung Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 1

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Boehringer Ingelheim300 enrolled12 locationsNCT04429087
Recruiting
Phase 2

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Neuroendocrine NeoplasmsSmall Cell Lung CarcinomaExtra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim204 enrolled59 locationsNCT05882058
Recruiting
Phase 3

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

Small Cell Lung Carcinoma
AstraZeneca70 enrolled15 locationsNCT06992609
Recruiting
Phase 1Phase 2

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC110 enrolled48 locationsNCT04938817
Recruiting
Phase 1Phase 2

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.118 enrolled4 locationsNCT07407933
Recruiting
Phase 3

Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial

Small Cell Lung Carcinoma
Instituto de Investigación Biomédica de Salamanca300 enrolled13 locationsNCT07015892
Recruiting
Phase 1

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Large Cell Neuroendocrine Carcinoma of the LungSmall Cell Lung CarcinomaNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals116 enrolled5 locationsNCT07006727
Recruiting
Phase 2

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Nonsmall Cell Lung Cancer Stage IIIUnresectable Non-Small Cell Lung CarcinomaNonsmall Cell Lung Cancer, Stage II
Wake Forest University Health Sciences28 enrolled1 locationNCT05696782
Recruiting
Early Phase 1

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Lung CancerSmall Cell Lung Carcinoma
UNC Lineberger Comprehensive Cancer Center24 enrolled1 locationNCT05620342
Recruiting
Phase 3

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

Non-Small Cell Lung Carcinoma (NSCLC)
Sinocelltech Ltd.246 enrolled1 locationNCT07362459
Recruiting
Phase 2

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Metastatic Squamous Non-Small Cell Lung Carcinoma
University of Illinois at Chicago36 enrolled1 locationNCT05613413
Recruiting
Phase 1Phase 2

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

Small Cell Lung CancerSmall Cell Lung Carcinoma
Memorial Sloan Kettering Cancer Center53 enrolled1 locationNCT04199741
Recruiting
Phase 1

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Small Cell Lung Carcinoma (SCLC)Neuroendocrine Neoplasms
Boehringer Ingelheim12 enrolled1 locationNCT05963867
Recruiting
Phase 2

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung Carcinoma
Genelux Corporation142 enrolled16 locationsNCT06463665
Recruiting
Not Applicable

Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer

Small Cell Lung Carcinoma
Copernicus Memorial Hospital165 enrolled2 locationsNCT06529081
Recruiting
Phase 3

Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

NSCLC (Non-small Cell Lung Carcinoma)First Line TherapyLocally Advanced/Metastatic NSCLC
Dr Arvindran A/L Alaga123 enrolled1 locationNCT07050043
Recruiting
Phase 2

Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

Small Cell Lung Carcinoma
UNICANCER100 enrolled32 locationsNCT05617963
Recruiting
Phase 1

Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors

NeoplasmsSmall Cell Lung Carcinoma (SCLC)Glioblastoma, Adult
Chipscreen Biosciences, Ltd.102 enrolled2 locationsNCT06902350
Recruiting

Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis

Immune Checkpoint Inhibitors-induced ColitisAdvanced Melanoma Skin Cancer, Non-small Cell Lung Carcinoma, Kidney AdenocarcinomaIleo-colitis+1 more
Fondazione IRCCS Policlinico San Matteo di Pavia250 enrolled1 locationNCT06899789
Recruiting

PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.

Small Cell Lung Carcinoma
University Hospital, Essen30 enrolled1 locationNCT06247163